Introduction
Anti-tumor necrosis factor alpha (TNFα) agents are effective in the treatment of Crohn’s disease (CD) and ulcerative colitis but may cause adverse effects including cytopenias (1). Anti-TNFα induced thrombocytopenia, although not common, is a recognized side effect. However, the exact mechanisms involved in anti- TNFα thrombocytopenia are unknown. We therefore present a case of adalimumab (anti-TNFα agent) - induced immune thrombocytopenia in a patient with CD in whom we were able to demonstrate drug-induced platelet antibodies. Moreover, we discuss the proposed mechanisms involved.